FCF Fox Company Finance GmbH is delighted to publish the brand new “FCF Life Sciences Enterprise Capital Monitor – Europe 09/2022”. The Monitor is a month-to-month printed overview of enterprise capital traits within the European Life Sciences sector.
As of the top of September 2022 we establish the next present VC traits in Europe:
- In 2022, total Life Sciences funding has reached EUR 7,887m thus far
- High 5 Offers exceed EUR 140m every, largest transaction amounted to EUR 500m in Doctolib (France)
- Bpifrance (France) dominates the High 5 Buyers (by deal quantity), adopted by Eurazeo (France) and Normal Atlantic (United States)
- Biotech obtained 43% of the whole funding quantity, (no change in comparison with the earlier month)
- Oncology nonetheless dominates as the highest indication in Biotechnology
To entry the complete report, please click on right here.
By Dr. Mathias Schott, Sebastian Sommer and Johannes Hyperlink